Liberty Health Sciences Inc. and Resolve Digital Health Inc. Strike Exclusive Partnership to Provide Floridians With Innovative Cannabis Metered-Dosing Inhalation Solutions

TORONTO, Oct. 11, 2017 /CNW/ - Liberty Health Sciences Inc. (CSE:LHS) (OTCBB:LHSIF) ("Liberty" or the "Company") today announced an exclusive partnership with Resolve Digital Health Inc. ("Resolve"), a cutting edge developer of medical cannabis delivery systems and devices.  The partnership will see Resolve's industry-leading smart inhalation products exclusively distributed through Liberty within the state of Florida, subject to approval of the same by the Florida Department of Health, Office of Medical Marijuana Use as is required under Florida law.

Liberty is committed to delivering high-quality, clean and safe pharmaceutical grade cannabis to patients in need and this partnership represents yet another important step in enhancing the patient experience. Resolve's smart technology is based on proprietary Artificial Intelligence algorithms that track patient usage data through a mobile application to facilitate sharing with doctors, pharmacists and other caregivers, and allows patients and health care professionals to monitor the efficacy of treatment in order to continuously improve their medical cannabis experience.

"Our partnership with Resolve further supports our commitment to being industry leaders in the medical cannabis space by offering our patients innovative and safe methods to inhale cannabis. The Aphria brand is dedicated to patient well-being which makes the Resolve inhaler a perfect addition to our product portfolio." said George Scorsis, CEO and Director of Liberty. "We're very pleased to be partnering with Resolve to bring their state-of-art technology, and a heightened understanding of patients' needs to the Florida market."

Resolve is committed to establishing the highest standard of care in the medical cannabis industry. Breeze Smart Inhalers, their metered-dose based vaporizer, works in conjunction with the Breeze App to provide a patent-pending adaptive dosing function. This allows patients to vary their dose based on their current levels of pain and through machine learning analysis of their activity patterns, time of day, local weather conditions, sleep history and other collected and reported data.

"Like Liberty, Resolve's top priority is patient care, and we're excited to be able to provide a truly unique medical service to patients in Florida thanks to this partnership," said Rob Adelson, CEO of Resolve. "Liberty's market expertise makes them the perfect partner to help provide patients with a sophisticated medical cannabis experience."

For more information on Liberty, please visit www.libertyhealthsciences.com  

About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal.  Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near and mid-term opportunities.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients. 

About Resolve Digital Health
Resolve Digital Health is positioned to be the leading provider of a metered dosing ecosystem for medical cannabis devices. The company's proprietary technology, apps and cloud-based health information platform, found in Resolve's debut product Breeze, address the numerous issues with currently available methods of cannabis delivery – establishing a standard of care and rigorous medical approach for the medical cannabis industry. With over three years of research and development, the complete product ecosystem will be initially available in select dispensaries in early 2018. For more information, visit:

www.mybreeze.co  
www.resolvedigitalhealth.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend", "subject to" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations concerning receipt of approval from the Florida Department of Health, Office of Medical Marijuana Use. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

For further information: For U.S. media inquiries, please contact: Ober Delgado, Edelman, [email protected], 305.358.2830; For Canadian media inquiries, please contact: Matt Salvatore, Edelman, [email protected], 613.315.7362; For Resolve Digital Health specific inquiries, please contact: Jennifer Bender, Resolve Digital Health, [email protected], 1-888-329-6560 x224